Trial Profile

Imatinib mesylate, busulfan, fludarabine, ATG and allogeneic stem cell transplantation for chronic myelogenous leukemia.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antithymocyte globulin; Busulfan; Fludarabine; Imatinib; Methotrexate; Tacrolimus
Indications Chronic myeloid leukaemia; Graft-versus-host disease
Focus Therapeutic Use

Most Recent Events

23 Apr 2012 Biomarkers information updated
24 Jan 2012 Actual patient number (42) added as reported by ClinicalTrials.gov.
24 Jan 2012 Tacrolimus and methotrexate identified as a components of treatment as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com